CXCL12 and pancreatic neoplasm: Moreover, CXCL12 predicted short RFS (p = 0.0001) (n = 48, PFS data were unavailable for 3/51 R0 patients) and CSS (p = 0.017) (n = 50, as 1 out of 51 R0 died from other cause than pancreatic cancer) in R0 patient’s subgroup (Figure 6B).